Evan S. Schwarz

Evan S. Schwarz

Auto-generated profile, based on publicly available information

Evan S. Schwarz

Division of Emergency Medicine, Washington University School of Medicine, St. Louis, MO, USA

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 October 2018 in Clinical Infectious Diseases
Verified
Journal Article
Closed access
PDF file
LMLaura R Marks
Laura R Marks
SMSatish Munigala
Satish Munigala
DWDavid K Warren
David K Warren
SLStephen Y Liang
Stephen Y Liang
ESEvan S Schwarz
Evan S Schwarz
MDMichael J. Durkin
Michael J. Durkin
The opioid epidemic has increased hospital admissions for serious infections related to opioid abuse. Our findings demonstrate addiction medicine consultation is associated with increased treatment for opioid use disorder (OUD), greater likelihood of completing antimicrobial therapy, and reduced readmissions among patients with OUD and serious infections requiring hospitalization.

2 August 2012 in Human & Experimental Toxicology
Verified
Journal Article
Closed access
MFMb Forrester
Mb Forrester
KKK Kleinschmidt
K Kleinschmidt
ESE Schwarz
E Schwarz
AYA Young
A Young
Synthetic cannabinoids have recently gained popularity as a recreational drug because they are believed to result in a marijuana-like high. This investigation compared synthetic cannabinoids and marijuana exposures reported to a large statewide poison center system. Synthetic cannabinoid and marijuana exposures reported to Texas poison centers during 2010 were identified. The distribution of exposures to the two agents with respect to various demographic and clinical factors were compared by calculating the rate ratio (RR) of the synthetic cannabinoid and marijuana percentages for each subgroup and 95% confidence interval (CI). The proportion of synthetic cannabinoid and marijuana exposures, respectively, were 87.3% and 46.5% via inhalation (RR 1.88, 95% CI 1.38–2.61), 74.9% and 65.7% in male (RR 1.14, 95% CI 0.87–1.51), 40.2% and 56.6% age ≤19 years (RR 0.71, 95% CI 0.52–0.98), 79.2% and 58.6% occurring at a residence (RR 1.35, 95% CI 1.02–1.82), 8.4% and 16.2% managed on-site (RR 0.52. 95% CI 0.28–1.00), and 59.3% and 41.4% with serious medical outcomes (RR 1.43, 95% CI 1.03–2.05). Compared to marijuana, synthetic cannabinoid exposures were more likely to be used through inhalation, to involve adults, to be used at a residence, and to result in serious outcomes.

1 September 2012 in The American Journal of Emergency Medicine
Verified
Journal Article
Closed access
AYAmy C. Young
Amy C. Young
ESEvan Schwarz
Evan Schwarz
GMGenevieve Medina
Genevieve Medina
AOAdebisi Obafemi
Adebisi Obafemi
SFSing-Yi Feng
Sing-Yi Feng
KKKurt Kleinschmidt
Kurt Kleinschmidt

4 March 2023 in Clinical Toxicology
Verified
Journal Article
Closed access
JLJennifer S. Love
Jennifer S. Love
MLMichael Levine
Michael Levine
KAKim Aldy
Kim Aldy
JBJeffrey Brent
Jeffrey Brent
AKAlex J. Krotulski
Alex J. Krotulski
AMAlex F. Manini
Alex F. Manini
Illicit opioids, consisting largely of fentanyl, novel synthetic opioids, and adulterants, are the primary cause of drug overdose fatality in the United States. Xylazine, an alpha-2 adrenergic agon...

17 July 2018 in Academic Emergency Medicine
Verified
Journal Article
Closed access
PDF file
NKNicholas Karlow
Nicholas Karlow
CSCharles H Schlaepfer
Charles H Schlaepfer
CSCarolyn R T Stoll
Carolyn R T Stoll
MDMichelle Doering
Michelle Doering
CCChristopher R Carpenter
Christopher R Carpenter
ESEvan S Schwarz
Evan S Schwarz

11 May 2017 in Clinical Toxicology
Verified
Journal Article
Closed access
LDLaurel Dezieck
Laurel Dezieck
ZHZachary Hafez
Zachary Hafez
ACAlbert Conicella
Albert Conicella
EBEike Blohm
Eike Blohm
MOMark J. O’connor
Mark J. O’connor
MMMichael E. Mullins
Michael E. Mullins
Cannabinoid hyperemesis syndrome (CHS) is characterized by symptoms of cyclic abdominal pain, nausea, and vomiting in the setting of prolonged cannabis use. The transient receptor potential vanilloid 1 (TRPV1) receptor may be involved in this syndrome. Topical capsaicin is a proposed treatment for CHS; it binds TRPV1 with high specificity, impairing substance P signaling in the area postrema and nucleus tractus solitarius via overstimulation of TRPV1. This may explain its apparent antiemetic effect in this syndrome. We describe a series of thirteen cases of suspected cannabis hyperemesis syndrome treated with capsaicin in the emergency departments of two academic medical centers. A query of the electronic health record at both centers identified thirteen patients with documented daily cannabis use and symptoms consistent with CHS who were administered topical capsaicin cream for symptom management. All 13 patients experienced symptom relief after administration of capsaicin cream. Topical capsaicin was associated with improvement in symptoms of CHS after other treatments failed.